Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures

SIMPLE SUMMARY: The approval of the two antibody combinations trastuzumab/pertuzumab and ipilimumab/nivolumab in oncology has paved the way for novel antibody combinations or oligoclonal antibody mixtures to improve their efficacy in cancer. The underlying biological mechanisms and challenges of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Larbouret, Christel, Gros, Laurent, Pèlegrin, André, Chardès, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465647/
https://www.ncbi.nlm.nih.gov/pubmed/34572847
http://dx.doi.org/10.3390/cancers13184620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465647/
https://www.ncbi.nlm.nih.gov/pubmed/34572847
http://dx.doi.org/10.3390/cancers13184620

Ejemplares similares